IP Library Granted Patent US 7,354,939
Granted Patent B2
US 7,354,939 · App. 11/128,870 · Granted Apr 8, 2008

Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto

Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,354,939
App. No.
11/128,870
Granted
Apr 8, 2008
Kind
B2
Abstract

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Claims (20)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is a C 1-6 aliphatic group, wherein R 1 is optionally substituted with up to 2 groups independently selected from —OR or —C 1-3 haloalkyl;

each R is independently hydrogen or C 1-4 aliphatic;

R 2 is R, fluoro, or chloro;

m is 0, 1, or 2; and

R 3 is hydrogen, C 1-3 aliphatic, fluoro, or chloro; wherein

each aliphatic group is, independently, a saturated or unsaturated straight or branched hydrocarbon chain or monocyclic non-aromatic hydrocarbon.

2. The compound according to claim 1 , wherein R 1 is C 1-4 aliphatic optionally substituted with —OR or —C 1-3 haloalkyl.

3. The compound according to claim 2 , wherein R 1 is C 1-4 aliphatic optionally substituted with —OH, —CHF 2 , —CH 2 F, or —CF 3 .

4. The compound according to claim 3 , wherein R 1 is isopropyl, 2-butyl, cyclopropyl, or ethyl, wherein each moiety is optionally substituted with —OH or —CF 3 .

5. The compound according to claim 1 , wherein R 2 is hydrogen, C 1-3 aliphatic, or chloro.

6. The compound according to claim 1 , wherein R 3 is hydrogen, methyl, or chloro.

7. A compound selected from the group consisting of:

8. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

9. The compound according to claim 1 , wherein:

R 1 is isopropyl or 2-butyl, wherein R 1 is optionally substituted with one —OH;

R 2 is H or Cl;

m is 1; and

R 3 is Cl or methyl.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 1, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037676/0031 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2006
From: MARTINEZ-BOTELLA, GABRIEL; HALE, MICHAEL; MALTAIS, FRANCOIS; STRAUB, JUDITH; TANG, QING
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 017232/0451 →
Continuity (2)
Provisional Application 6057130900 · May 14, 2004
Related Publication 20060106069A1 · May 18, 2006